Compare TRX & HBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRX | HBIO |
|---|---|---|
| Founded | 1990 | 1901 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Laboratory Analytical Instruments |
| Sector | | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 383.1M | 26.5M |
| IPO Year | 2002 | 2000 |
| Metric | TRX | HBIO |
|---|---|---|
| Price | $1.32 | $8.10 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 2 |
| Target Price | $1.70 | ★ $18.00 |
| AVG Volume (30 Days) | ★ 2.9M | 16.7K |
| Earning Date | 04-15-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $116,176,000.00 |
| Revenue This Year | $84.84 | $4.77 |
| Revenue Next Year | $96.90 | $8.55 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.54 | $0.38 |
| 52 Week High | $2.80 | $8.40 |
| Indicator | TRX | HBIO |
|---|---|---|
| Relative Strength Index (RSI) | 60.95 | 64.75 |
| Support Level | $1.23 | $5.91 |
| Resistance Level | $1.31 | $8.40 |
| Average True Range (ATR) | 0.07 | 0.26 |
| MACD | -0.00 | -0.06 |
| Stochastic Oscillator | 80.43 | 32.36 |
TRX Gold Corp is a high-margin and growing gold company advancing the Buckreef Gold Project in Tanzania. Buckreef Gold includes an established open-pit operation and approximately 2,000 tonnes per day process plant with upside potential demonstrated. The group is focused on creating both near-term and long-term shareholder value by increasing gold production to generate positive cash flow to fund the expansion as outlined in the PEA and grow Mineral Resources through exploration. TRX Gold's actions are led by the highest environmental, social, and corporate governance (ESG) standards, evidenced by the relationships and programs that the Company has developed during its nearly two decades of presence in the Geita Region, Tanzania.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.